Dendreon shares Left for Dead?
There are the crazy price targets such as $18 by Maxim Group set in September and more reasonable $7 from Baird back in August. Going with BofA would represent a 44% increase to get back to $6 from today's price. Take a look at the crack price tp of $18, a 300%+ increase in the next 12 months...really?
|Ticker||Current Price||Target Price||% Increase|
Dendreon reports Q3 earnings at the end of the month on October 30th. Expect the stock to tread water until we hear something at that time. What could work for playing the conference call is a covered call on DNDN to protect your neck.
MASTERY Bottom line:
Provenge has a bunch of competition and when it costs $100K per patient, its not going to everyone who could really benefit from it.
Medivation (MDVN) and Astellas Pharma (ALPMY.PK) are getting ready to take on Provenge with their prostate cancer fighting drug Xtandi. There is room in the prostate cancer arena, these drugs are used at different stages of treating prostate cancer. Johnson & Johnson's (JNJ) Zytiga is also competing in this space as is Jevtana from Sanofi. The prostate cancer treatment field is getting crowded, its why DNDN has tanked to $4.
However Dendreon isn't dead yet. The stock can go lower but at $4 its worth a few bucks to go long.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Germany Slams Trump Criticism: Urges US To "Build Better Cars", Accuses Washington Of Causing Refugee Crisis | ZeroHedge
- Oil Slides After Saudis Suggest Early End To OPEC Deal | ZeroHedge
- In Scathing Attack, CIA Director Brennan Warns Trump To "Watch What He Says" | ZeroHedge
- The Eight Forces That Are Pressuring Profits | Financial Sense
- Abolish The CIA | ZeroHedge
- A Major Problem Emerges For The Davos Elite | ZeroHedge
- India Pays the Price of Demonetization | Financial Sense
The most relevant financial news and articles from the Internets
- The rise of Larry Ellison, the jet-setting billionaire founder of Oracle (ORCL) | Business Insider
- Amazon's Hit Man | BusinessWeek
- Explosive memos suggest that a Trump-Russia quid pro quo was at the heart of the... | Business Insider
- THE CHATBOT MONETIZATION REPORT: Sizing the market, key... | Business Insider
- The new era of payment processing will change everything | Business Insider
- Germany to the US after Trump remarks: 'Build better... | Business Insider
- China’s ambitious agenda is on track to make two groundbreaking... | Business Insider